Ozempic Patent Expiry Drives Surge in Pharma Stocks Ahead of Launch

Ajanta Pharma, Sun Pharma, and Lupin are in focus today as pharma stocks see a strong uptick, with Ozempic Patent Expiry emerging as a key trigger that drives surge in pharma stocks ahead of launch, as companies gear up to tap into the fast-growing diabetes and weight-loss drug market.

The patent for semaglutide, the active ingredient in Ozempic and Wegovy, is set to expire around March 20, opening the market for lower-cost generic versions. The Ozempic patent expiry is expected to trigger intense competition as Indian drugmakers move quickly to launch semaglutide generics.

Lupin has already partnered with Zydus for co-marketing, while Sun Pharma and other players are lining up approvals and scaling production. The entry of generics is likely to bring down prices significantly, improving access in a country with a large diabetic population and rising obesity cases.

Lower pricing could expand usage beyond urban centers, driving volumes higher. At the same time, competition is expected to increase sharply, with multiple companies entering the space. Early movers with strong distribution networks and doctor relationships may gain a clear edge.

The opportunity is not limited to India. With patent timelines aligning across regions, semaglutide generics are expected to expand into key global markets, increasing the overall revenue potential for manufacturers.

Also Read: How Digital Maturity is Powering Pharma's GMP Evolution

Semaglutide is widely prescribed for adults with type 2 diabetes to manage blood sugar levels. It is also used for weight management in adults and adolescents aged 12 and above who are overweight or obese, especially when linked to conditions such as high blood pressure or heart disease. The growing awareness around obesity treatment has boosted demand for such therapies.

The drug does come with side effects. Common reactions include nausea, diarrhea, constipation, and abdominal pain, which are usually mild to moderate and improve over time. Other effects such as fatigue, headaches, dizziness, heartburn, and injection site reactions have also been reported. In rare cases, more serious risks like gallbladder issues, pancreatitis, and potential thyroid tumor concerns may occur.

Market data shows strong growth potential. The semaglutide segment in India was valued at  INR 4.12 billion as of June 2025, while tirzepatide stood at  INR 500 million. The overall obesity drug market has grown fivefold since 2021 to reach INR 6.28 billion. Eli Lilly’s Mounjaro has seen rapid traction, while Novo Nordisk’s Wegovy continues to build presence, with semaglutide dominating market share.

Investors are now watching how companies execute their launch strategies. While the Ozempic patent expiry opens a major opportunity, pricing pressure and competition could impact margins in the near term.

Detailed Report

Generic alternatives expected to enter these countries

• Canada
• India
• Brazil
• Turkey

Who Is it For

• Adults with type 2 diabetes to manage blood sugar
• Adults and adolescents (12+) who are overweight or obese
• Patients with related conditions like high blood pressure or heart disease

Side effects

• Nausea
• Diarrhea
• Constipation
• Abdominal pain

Other potential effects

• Fatigue
• Headaches
• Dizziness
• Heartburn
• Injection site reactions

Serious but rare risks

• Gallbladder issues
• Pancreatitis
• Potential thyroid tumor risks

Market size in India

• Semaglutide market valued at  INR 4.12 billion (June 2025)
• Tirzepatide market valued at  INR 500 million
• Obesity drug market reached  INR 6.28 billion, growing fivefold since 2021
• Mounjaro sales doubled in June to 87,986 units worth  INR 260 million
• March–May Mounjaro sales stood at 81,570 units
• Wegovy recorded 1,788 units sold with  INR 25.3 million in sales
• Semaglutide holds around two-thirds market share in India
• Tirzepatide accounts for about 8 percent of the market